Phase 4
Completed N=41
Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
Loiasis
Source: ClinicalTrials.gov NCT05085665 ↗
Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Sep 2022
Primary outcomePrimary: Cross-reactive Antigenemia — 12 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cross-reactive Antigenemia |
12 | — |
Eligibility Criteria
Inclusion Criteria
- Loa loa blood microfilariae of between 5,000 - 18,000 per mL
Exclusion Criteria
- known allergy to ivermectin; severe comorbidities
Data sourced from ClinicalTrials.gov (NCT05085665). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.